ClinicalTrials.gg
RecruitingNCT06850805Re-Open 3Updated Sep 18, 2026

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

A Phase 3 interventional study of OPN-375 and Placebo in Chronic Rhinosinusitis Without Nasal Polyps, sponsored by Optinose US Inc.. Recruiting at 24 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Optinose US Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Planned enrollment
31st of 71
84 · median 60
Started
2025
with 4 others
Phase 3
25 of 83
4 open now
Primary completion
2028-03
later than 14 of 19 live
Registered
72nd of 83
by date
Lead sponsor
4 of 83
Optinose US Inc.

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 31st largest by planned enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2025, is one of 25 in phase 3, reaches primary completion later than 14 of the 19 other live ones, and was the 72nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with chronic rhinosinusitis without nasal polyps. The total planned number of subjects is approximately 84 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 1:1 ratio (OPN-375 186 µg:placebo). The study includes a PK sub-study, in which up 14 subjects will be enrolled to obtain 10 completers.

Read the detailed description

The primary objective of this study is to compare the efficacy of intranasal administration of OPN-375 (fluticasone propionate)186 µg twice a day (BID) versus placebo in adolescents with chronic rhinosinusitis (CRS) without nasal polyps (sNP) using the endpoint of change from baseline in CRS symptoms as measured by a 7-day average instantaneous composite score of nasal symptoms (CSS) at the end of Week 4. The CSS is the sum of scores assigned to the symptoms congestion, facial pain or pressure sensation, and nasal discharge (anterior and/or posterior), on a scale of 0 (non-symptomatic) to 3 (severe symptoms). The total CSS can range from 0-9. Eligible study subjects will complete a 7 to 21 day screening period followed by a 12-week double-blind treatment period, for a total of approximately 15 weeks of participation. The study consists of 3 on-site study visits (screening/V1, randomization/V2, end of study/V3/Week 12) and two telephone calls at participation weeks 4 and 8.

The study will include a pharmacokinetic (PK) substudy in which PK assessment of 186 µg OPN-375 in up to 14 study subjects will be conducted in an open label fashion.

03

Conditions studied

  • Chronic Rhinosinusitis Without Nasal Polyps

Keywords

  • Chronic Sinusitis
  • Chronic Rhinosinusitis
  • XHANCE
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 12 to 17 years, inclusive, at time of Visit 1 (Screening)
  2. Female subjects, if sexually active, must:

    1. be practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
    2. be surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
    3. be abstinent.
  3. Females of must have a negative urine pregnancy test at Visit 1 (Screening).
  4. Must have a history of CRS and be currently experiencing 2 or more of the following symptoms, 1 of which has to be either nasal congestion or nasal discharge (anterior and/or posterior nasal discharge) for equal to or greater than 12 weeks:

    • nasal congestion
    • nasal discharge (anterior and/or posterior nasal discharge)
    • facial pain or pressure
    • reduction or loss of smell
  5. Must have endoscopic evidence of nasal mucosal disease, with edema, or purulent discharge bilaterally, or presence of bilateral disease on a prior computed tomography (CT) scan performed within 14 days of Visit 1.
  6. Must have at least moderate symptoms (as defined in protocol) of nasal congestion as reported by the subject, on average, for the 7-day period preceding Visit 1 (Screening) run-in.
  7. Must have an average morning score of at least 1.5 for congestion on the Nasal Symptom Scale (as defined in protocol) recorded on the subject diary over a 7-day period during the first 14 days of the single-blind run-in period.
  8. Must demonstrate an ability to correctly complete the daily diary during the run-in period to be eligible for randomization.
  9. Subjects with comorbid asthma must be stable, defined as no exacerbations (e.g., no emergency room visits, hospitalization, or oral or parenteral use) within the 3 months before Visit 1 (Screening). Subjects who received inhaled corticosteroids are required to be on no more than a moderate dosage regimen as defined by 2021 Global Initiative for Asthma Guidelines (GINA) for 1 month before Visit 1 (Screening), and are expected to remain on it throughout the study. Subjects receiving inhaled fluticasone alone or in combination may not participate in the PK sub-study.
  10. Subjects with aspirin exacerbated respiratory disease, who have undergone aspirin desensitization and are receiving daily aspirin therapy, must be receiving therapy for at least 6 months prior to Visit 1.
  11. Must be able to cease treatment with intranasal steroids, inhaled corticosteroids (except permitted doses listed above for asthma) at the screening visit
  12. If taking oral antihistamines, must be on a stable regimen for at least 2 weeks prior to Visit 1 (Screening), and agree to not change the dose of these medications until after Week 4 of the study.
  13. Must be able to use the exhalation delivery system (EDS) correctly; all subjects will be required to demonstrate correct use with the practice EDS at Visit 1 (Screening).
  14. Must be capable, in the opinion of the investigator, of providing assent and parent or guardian must provide to participate in the study. Subjects must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and that they are willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant or lactating.
  2. Inability to have each nasal cavity examined for any reason, including nasal septum deviation.
  3. Inability to achieve bilateral nasal airflow.
  4. Is currently taking XHANCE®.
  5. Have previously used XHANCE for more than 1 month and did not achieve an adequate symptomatic response.
  6. History of sinus or nasal surgery within 6 months before Visit 1 or has not healed from a prior sinus or nasal surgery.
  7. Have current evidence of odontogenic sinusitis, sinus mucocele (the affected sinus is completely opacified and either the margins are expanded and/or thinned OR there are areas of complete bone resorption resulting in bony defect and extension of the "mass" into adjacent tissues), evidence of allergic fungal sinusitis, or evidence of complicated sinus disease (including, but not limited to, extension of inflammation outside of the sinuses and nasal cavity).
  8. Have a paranasal sinus or nasal tumor.
  9. Have a nasal polyp score of grade 1 or greater in either nostril as determined by the nasoendoscopy at screening.
  10. Have a nasal septum perforation.
  11. Have had more than 1 episode of epistaxis with frank bleeding in the month before Visit 1 (Screening).
  12. Have evidence of significant mucosal injury, ulceration (eg, exposed cartilage) on Visit 1 (Screening) nasal examination/nasoendoscopy.
  13. Have current, ongoing rhinitis medicamentosa (rebound rhinitis).
  14. Have significant oral structural abnormalities (eg, a cleft palate).
  15. Have a diagnosis of cystic fibrosis.
  16. History of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
  17. Symptom resolution or last dose of antibiotics for purulent nasal infection, acute sinusitis, or upper respiratory tract infection, influenza, or SARS-CoV-2 (COVID-19) has not occurred before Visit 1. Potential subjects presenting with any of these infections may be rescreened 4 weeks after symptom resolution.
  18. Planned sinonasal surgery during the period of the study.
  19. Allergy, , or to or steroids.
  20. Has used oral steroids in the past for treatment of CS and did not experience any relief of symptoms.
  21. Has a steroid eluting sinus stent still in place within 30 days of Visit 1.
  22. Allergy or hypersensitivity to any in study drug.
  23. Exposure to any glucocorticoid treatment with potential for systemic effects (eg, oral, parenteral) within 1 month before Visit 1 (Screening); except as noted in inclusion criteria for subjects with comorbid asthma or .
  24. Have nasal or oral candidiasis.
  25. History or current diagnosis of any form of glaucoma or ocular hypertension.
  26. History of IOP elevation on any form of steroid therapy.
  27. History or current diagnosis of the presence (in either eye) of a cataract unless both natural intraocular lenses have been removed.
  28. History of immunodeficiency of any etiology (including poor nutrition) that would be anticipated to affect the likelihood of benefit or harm from the therapeutic intervention.
  29. Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator could confound the results of the study or could interfere with the subject's participation or compliance in the study.
  30. Have a positive drug screen or a history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the subject's participation or compliance in the study.
  31. Have participated in an drug clinical trial within 30 days of Visit 1 (Screening).
  32. Have received mepolizumab (Nucala®), reslizumab (Cinquair®), dupilumab (Dupixent®), omalizumab (Xolair®), benralizumab (Fasenra™), Tezepelumab-ekko (Tezspire®) or any other immune-modifying monoclonal antibody within 6 months of Visit 1 (Screening).
  33. Is using strong cytochrome P450 3A4 () inhibitor (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole, cobicistat).
  34. Has a parent, guardian or caregiver who is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, or is a family member of the employee or the investigator.
  35. Patients who report unexplained worsening of vision within the past 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Placebo comparator
    Placebo BID

    Double-Blind Treatment Phase: Intranasal administration of matching placebo BID x 12 weeks

    Drug: Placebo

  • Active comparator
    OPN-375 186 µg BID

    Double-Blind Treatment Phase: Intranasal administration of OPN-375 186 µg x 12 weeks

    Drug: OPN-375

Interventions

  • OPN-375 (fluticasone propionate) delivered via exhalation delivery system (EDS) BID

  • DrugPlacebo

    Placebo solution administered via exhalation delivery system (EDS).

06

What researchers measure

Primary outcomes

  1. Change from baseline to the end of Week 4 in the average instantaneous CSS (evaluation of symptom severity immediately preceding the time of scoring).

    The CSS consists of the sum of the scores (0-3) assigned to each of the following symptoms of CRS: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The total CSS for each day can range from 0 to 9. Participants will report symptom severity immediately preceding the time of scoring every morning (AM). The baseline CSS is the average of the CSS's over the last 7 days of the single-blind run-in period. The end of Week 4 CSS is the average of the CSS's over the 7 days before Week 4.

    Time frame: 4 Weeks

Secondary outcomes

  1. Frequency of acute exacerbations of CRS over the 12-week treatment period

    Acute exacerbations of CRS (AECRS) are defined as a worsening of symptoms that requires an escalation of treatment. The number of AECRS experienced by each participant will be recorded.

    Time frame: 12 weeks

  2. Change from baseline to the end of Week 4 on CSS score in subjects using an intranasal steroid treatment for CRS within 30 days of Visit 1/Screening

    The CSS consists of the sum of the scores (0-3) assigned to each of the following symptoms of CRS: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The total CSS for each day can range from 0 to 9. Participants will report symptom severity immediately preceding the time of scoring every morning (AM). The baseline CSS is the average of the CSS's over the last 7 days of the single-blind run-in period. The end of Week 4 CSS is the average of the CSS's over the 7 days before Week 4. This outcome will assess this change in CSS specifically in the subgroup of participants who were symptomatic at trial entry despite reported use of an intranasal steroid for treatment of CRS within 30 days of Visit 1/Screening.

    Time frame: 4 Weeks

  3. Change from baseline to the end of Weeks 8 and 12 in CSS

    The CSS consists of the sum of the scores (0-3) assigned to each of the following symptoms of CRS: nasal congestion, nasal discharge (anterior and/or posterior), facial pain/pressure sensation, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. The total CSS for each day can range from 0 to 9. Participants will report symptom severity immediately preceding the time of scoring every morning (AM). The baseline CSS is the average of the CSS's over the last 7 days of the single-blind run-in period. The CSS for the end of Week 8 and Week 12 is the average of the CSS's over the 7 days before Week 8 and Week 12, respectively.

    Time frame: 8 Weeks; 12 Weeks

  4. Change from baseline to the end of Weeks 4, 8 and 12 in four separate cardinal CRS symptoms

    Participants will rate each of the following four cardinal symptoms of CRS every morning based on symptom severity immediately before reporting: nasal congestion, facial pain or pressure sensation, nasal discharge (anterior and/or posterior), and sense of smell. Participants will rate each symptom on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms, and 3 = severe symptoms. Scores from the 7 days immediately preceding each timepoint will be averaged. The change in 7-day average score from baseline to Week 4, Week 8, and Week 12 for each symptom will be assessed individually.

    Time frame: 4 Weeks; 8 Weeks; 12 Weeks

  5. Percent of subjects indicating improvement on the Patient Global Impression of Change (PGIC) at Week 12/ end of study.

    The Patient Global Impression of Change (PGIC) survey consists of a single question asking participants to rate how much their symptoms have changed since beginning use of the study drug on a scale of 1 to 7, where 1 = Very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The percent of subjects indicating any improvement (minimal, much, or very much) will be assessed.

    Time frame: 12 Weeks

  6. Change from baseline to Week 12 in the 5 domains of the SN-5 Questionnaire

    The SN-5 questionnaire is a quality of life assessment that will be completed by the participant/parent. There are 5 specific symptom related questions (answered on a 7-point Likert scale on frequency of symptoms, where 1 = none of the time and 7 = all of the time), and 1 general quality of life question, answered on a visual analog scale from 0 (worst) to 10 (best). For this outcome, the change in score from baseline to Week 12/end of participation will be assessed for each of the 5 symptom related questions.

    Time frame: 12 Weeks

  7. Change from baseline to Week 12 in overall quality of life as measured by the SN-5 Questionnaire

    The SN-5 questionnaire is a quality of life assessment that will be completed by the participant/parent. There are 5 specific symptom related questions (answered on a 7-point Likert scale on frequency of symptoms, where 1 = none of the time and 7 = all of the time), and 1 general quality of life question, answered on a visual analog scale from 0 (worst) to 10 (best). This outcome will assess the change in score from baseline to Week 12/end of participation for general quality of life question.

    Time frame: 12 Weeks

Other outcomes

  1. Assessment of safety through Adverse Events (AEs)

    Safety will be assessed by reporting frequency and severity (mild, moderate, or severe) of AEs experienced by participants during the trial. AEs will be collected beginning at time of signing of the Informed Consent Form (ICF) through end of participation (Week 12 or early termination).

    Time frame: 12 Weeks

  2. Assessment of safety by nasal examination

    Nasal examinations will be completed on all participants via nasoendoscopy at screening and end of study (Week 12 or early termination). Physicians performing the nasoendoscopies will record the presence of epistaxis, septal erosion/perforation, and details related to ulceration/erosion of any area other than the septum. The frequency and severity of findings from these exams will be reported.

    Time frame: 12 Weeks

  3. Assessment of safety by ocular examination visual acuity

    Ocular examinations will be performed during screening period and end of participation (Week 12 or early termination), and will include an assessment of visual acuity. Visual acuity will be assessed using an eye chart (EVA, EDTRS or Snellen) and will be recorded for each eye in the form of a fraction: 20/x.

    Time frame: 12 Weeks

  4. Assessment of safety by ocular examination intraocular pressure (IOP)

    Ocular examinations will be performed during screening period and end of participation (Week 12 or early termination), and will include an assessment of intraocular pressure. Intraocular pressure will be assessed using a Goldmann applanation tonometer mounted on a slit lamp, a hand-held applanation Goldmann-type tonometer, or a Tono-Pen. Two measurements will be performed for each eye. If the first 2 measurements differ by more than 3 mm Hg, a third measurement will be performed. The average value of the 2 or 3 measurements will be calculated. Subjects in whom IOP is elevated above 21 mm Hg will not be enrolled. Any new occurrence of intraocular pressure elevation above 21 mm Hg will require subject withdrawal.

    Time frame: 12 Weeks

  5. Assessment of safety by ocular examination for cataracts

    Ocular examinations will be performed during screening period and end of participation (Week 12 or early termination), and will include an assessment of presence of cataracts. Each of the participant's eyes will be assessed for the presence of cataracts. If a cataract is identified, it will be specified based on type (nuclear, cortical, or posterior subcapsular) and assigned a grade of 1, 1+, 2, 2+, 3, 3+, or 4. Participants with cataracts at screening will not be enrolled. Any new occurrence of cataracts of any grade will require withdrawal from the study.

    Time frame: 12 Weeks

  6. Assessment of safety by weight measurement

    Participant weight will be collected at screening, randomization and end of participation (Week 12 or early termination). Weight will be measured in kilograms or pounds and findings will be summarized using descriptive statistics including mean values and change from baseline values, as well as numbers of subjects with values outside limits of the normal range at each time point.

    Time frame: 12 Weeks

  7. Assessment of safety by measuring vital signs - blood pressure

    Participant blood pressure measurements will be collected at screening, randomization and end of participation (Week 12 or early termination). Systolic and diastolic blood pressure measurements will be collected in millimeter of mercury (mmHg) and findings will be summarized using descriptive statistics including mean values and change from baseline values, as well as numbers of subjects with values outside limits of the normal range at each time point.

    Time frame: 12 Weeks

  8. Assessment of safety by measuring vital signs - pulse

    Participant heart rate will be collected at screening, randomization and end of participation (Week 12 or early termination). Heart rate will be measured in beats per minute (bpm) and findings will be summarized using descriptive statistics including mean values and change from baseline values, as well as numbers of subjects with values outside limits of the normal range at each time point.

    Time frame: 12 Weeks

  9. Assessment of safety through collection of concomitant medication usage information

    Use of concomitant medications and related information will be collected from time of ICF signing through end of participation (Week 12 or early termination). Concomitant medications will be coded using the World Health Organization (WHO) Drug Dictionary (WHODrug) and summarized by drug class with subject counts and percent.

    Time frame: 12 Weeks

07

Study locations

19 of 24 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2028, 32 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 32 months is above that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 27, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Oct 31, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06850805
Lead sponsor
Optinose US Inc.
Collaborators
Paratek Pharmaceuticals Inc
Responsible party
Sponsor
First posted
Feb 27, 2025
Start date
Jul 28, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Alissa Sirbu
Contact
alissa.sirbu@paratekpharma.com
484-751-4926
Amy Manley
study chair · Paratek Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion